Stop CMV Act of 2025
- Bill Number
- S. 2842
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-17: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-03-18T11:03:18Z
AI-Generated Summary
Purpose
The "Stop CMV Act of 2025" aims to promote early detection of congenital cytomegalovirus (CMV), a common virus that can infect newborns during pregnancy and lead to hearing loss, vision problems, or developmental delays if untreated. By mandating screening for this condition in newborns, the legislation seeks to enable timely diagnosis, intervention, and education to reduce health risks for affected infants.
Key Provisions
- Screening Requirement: Hospitals and other health care facilities must test all infants 21 days old or younger for congenital CMV, as designated by the Secretary of Health and Human Services (HHS). This includes processes for recording results, tracking cases, follow-up care, and education.
- State Responsibilities: Each state's chief health officer can set standards for testing procedures, result dissemination to parents or guardians, and related activities. If a state fails to establish approved standards within two years of enactment, the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (an expert panel under HHS) will provide them.
- Advisory Committee Role: The committee reviews and approves state standards, drawing on practices from other states, existing newborn screenings for genetic conditions, and relevant scientific evidence.
- Federal Grants and Support:
- HHS, through the Health Resources and Services Administration (HRSA), provides grants to states for distributing funds to health care entities to conduct screenings (authorized funding for fiscal years 2026 and 2027).
- HHS, through the Centers for Disease Control and Prevention (CDC), offers grants or agreements to states for improving data collection on CMV and educating health providers, patients, and the public on prevention, symptoms, diagnosis, and treatment (also authorized for 2026 and 2027).
- The National Institutes of Health (NIH) must initiate or expand research programs on CMV screening techniques, interventions, diagnostics, prevention (including awareness campaigns and vaccines), and treatments for both pregnant individuals and newborns, using existing unobligated funds.
- Amendments to Advisory Committee: The committee's duties are expanded to oversee CMV screening activities.
Significant Changes to Existing Law
- Inserts a new section (1116A) into Part A of Title XI of the Public Health Service Act (42 U.S.C. 300b et seq.), which previously focused on other newborn screenings but did not specifically address congenital CMV.
- Expands the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children's responsibilities to include CMV-related activities, making it a key overseer for implementation.
- Introduces new federal grant programs targeted at CMV, building on but not altering existing newborn screening frameworks for conditions like phenylketonuria (PKU) or sickle cell disease.
Potential Impacts
- On Government Agencies: Increases workload for HHS agencies (HRSA, CDC, NIH) in grant administration, research funding, and oversight; states may need to update public health systems for data tracking and education, potentially straining resources without additional state funding.
- On Citizens: Newborns and families could benefit from earlier CMV detection, leading to interventions like antiviral treatments that might prevent long-term disabilities; parents gain better access to information on risks and prevention, though it may raise awareness of a previously underrecognized condition.
- On International Relations: Minimal direct impact, as the bill focuses on domestic public health; however, NIH research on vaccines and treatments could contribute to global health efforts if findings are shared internationally.
- Overall, the act could standardize CMV screening nationwide, similar to routine newborn heel-prick tests, potentially improving infant health outcomes and reducing long-term health care costs.
Main Stakeholders Affected
- Newborns and Families: Primary beneficiaries through early screening and education to mitigate CMV risks.
- Health Care Providers: Hospitals and clinics must implement testing, facing new operational requirements but gaining federal grant support.
- State Health Departments: Responsible for standards, data systems, and dissemination, with flexibility but potential federal intervention if delayed.
- Federal Agencies: HRSA, CDC, and NIH handle grants, technical assistance, and research expansion.
- Researchers and Advocacy Groups: Benefit from NIH funding for CMV studies; groups focused on congenital conditions (e.g., those supporting hearing or developmental health) may influence implementation.
- General Public: Indirectly affected through public education on CMV prevention, such as hygiene practices during pregnancy.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens public health mandates under the Public Health Service Act without creating new enforcement penalties; relies on voluntary state compliance with federal backstops, avoiding direct federal overreach. The bill's use of existing advisory structures ensures evidence-based standards, potentially reducing legal challenges over medical necessity.
- Constitutional: Aligns with Congress's authority to regulate public health and provide for the general welfare (Article I, Section 8); no apparent conflicts with privacy rights (e.g., under the Fourth Amendment), as parental notification is required and testing is non-invasive.
- Political: Bipartisan sponsorship (Democrats and Republicans) suggests broad support for pediatric health initiatives; could set a precedent for adding more conditions to the federal recommended uniform screening panel, influencing future debates on newborn testing expansion amid concerns over costs and equity in rural or underserved areas.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Blumenthal, Richard [D-CT]
Cosponsors (4)
Sen. Marshall, Roger [R-KS], Sen. Kelly, Mark [D-AZ], Sen. Murphy, Christopher [D-CT], Sen. Klobuchar, Amy [D-MN]
Recent Actions
- 2025-09-17: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-09-17: Introduced in Senate
Bill Versions
- Stop CMV Act of 2025 — issued 2025-09-17 — PDF (7 pages)